Compared with doxorubicin plus cyclophosphamide, docetaxel plus cyclophosphamide was highly cost-effective for adjuvant treatment of operable breast cancer.
Stephen E. Jones, MD
Advertisement
Articles by Stephen E. Jones, MD
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Docetaxel-Cyclophosphamide Versus Doxorubicin-Cyclophosphamide for Breast Cancer
Published: October 1st 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Blenrep Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
2
Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms Across OASIS Clinical Trials
3
G-CSF is a Potential Alternative in Treatment of Hot Flashes in Postmenopausal Women
4
CHEST 2025: Advancing Respiratory Virus Vaccines and Improving Uptake Among High-Risk Populations
5
